Tasquinimod or pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
DE602022021929T2Active Publication Date: 2025-09-24ACTIVE BIOTECH AB
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- DE602022021929
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-10-29
- Filing Date
- 2022-01-17
- Publication Date
- 2025-09-24
- Estimated Expiration
- 2042-01-17
AI Technical Summary
Technical Problem
Myelodysplastic syndromes (MDS) have limited treatment options, with allogeneic hematopoietic stem cell transplantation being the only curative option, which is not feasible for many patients, and existing drug therapies primarily focusing on supportive care and limited efficacy.
Method used
Tasquinimod or its pharmaceutically acceptable salts are used to treat MDS by targeting the immunomodulatory protein S100A9, inhibiting inflammatory pathways, and enhancing hematopoietic progenitor cell function.
Benefits of technology
Tasquinimod improves hematological parameters in MDS patients by reducing myoblasts, increasing hemoglobin and platelet counts, and reducing transfusion dependence, thereby addressing the limitations of current treatments.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.